Introduction:
Assessing therapeutic responses early during the course of cancer therapy is important because non-responding patients can be switched to alternative management strategies including earlier surgical resection. This is of particular importance when patients undergo marginally beneficial treatments. One such example is the frequently employed but still controversial neoadjuvant chemo-or chemoradiation therapy of patients with soft tissue sarcoma (STS) (3) .
STSs are associated with an overall 5 year survival rate of approximately 50% (4) . Patient prognosis depends on tumor grade, size, histology, depth, surgical margins and the presence of metastasis at the time of diagnosis. Moreover, histopathological response to neoadjuvant chemo-or chemo/radiation therapy has also been shown to predict patient outcome (5, 6) .
Only 20-30% of patients with STS achieve a significant histopathologic response to neoadjuvant treatment (1, 2). Intermediate endpoint biomarkers to identify treatment responders and non-responders early during therapy are therefore needed to reduce side effects and costs of ineffective treatments (7) (8) (9) . 18 F-FDG-PET imaging has been used to identify histopathologic treatment responders at the end of (1) and as early as after one cycle (2) of neoadjuvant therapy. Similar results were also reported from other institutions (10, 11).
Based on these encouraging findings we hypothesized that early and late changes in tumor FDG uptake might predict long term survival of patients with STS undergoing neoadjuvant therapy. Correlations between PET findings and histopathological response have been reported previously (1, 2). Exclusion criteria were patient age of < 18 years, chemo-and/or radiotherapy within 6 months prior to the baseline PET/CT scan, presence of a second malignancy, unresectable disease, and a diagnosis of gastrointestinal stromal tumor (GIST). In addition, 21/78 patients (27%) were excluded from this analysis as they presented with recurrent and/or metastatic disease at the time of the baseline scan (primary and concurrent metastatic disease in 8 patients, recurrent disease in 5 patients, and recurrent metastatic disease in 8 patients, respectively). Thus, the current study population consisted of 57 patients with primary, non-metastatic soft tissue sarcoma who underwent neoadjuvant therapy followed by surgery (Table 1) . The study was approved by the UCLA IRB and all patients provided written informed consent for their participation. Forty-six patients (81%) received neoadjuvant external beam radiation starting after the first cycle of chemotherapy and following the early follow up PET/CT scan. Eleven patients (19%) received no radiation therapy due to location or extent of the primary disease.
PET/CT imaging. All 57 patients underwent a baseline scan prior to initiation of chemotherapy. A second (early follow up) study was performed in 39 patients after the initial cycle of chemotherapy and prior to radiation treatment. 36 of these 39 patients had been previously studied for correlation between histopathological response and PET findings. Seventeen/18 patients not undergoing the early follow up scan were included into this study prior to January 2006. An end-oftreatment scan (late follow up) was performed in 56 patients. One patient had rapid clinical progression after the first cycle of chemotherapy and opted for surgery before undergoing the late follow up scan. 38 patients underwent both, the early and late follow up scans. and 104.7±37.6 (median: 98.0) days respectively after the baseline PET/CT study. Median time from late follow up PET/CT to surgery was 7.0 days.
All PET/CT studies were performed using the Siemens ® Biograph Duo. The image acquisition protocol was reported before (12) . In brief, after a minimum fasting period of 6 hours serum glucose levels were below 180 mg/dl in all patients. Patients received 0.21 mCi/kg of 18 F-FDG-PET intravenously. PET emission scans were acquired using a weight based protocol and during shallow breathing as reported previously (13) (14) (15) . PET images were reconstructed using an iterative algorithm (OSEM two iterations, eight subsets). The CT acquisition parameters were 130 kVp, 120 mAs, 1-s tube rotation, 4-mm slice collimation, and a bed speed of 8-mm/s. The CT images were reconstructed using filtered back-projection, at 3.4 mm axial intervals to match the slice separation of the PET data. A previously published CT-based algorithm was used for attenuation correction (16) .
Image analysis.
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F-FDG-PET images were analyzed by one observer who was aware of the clinical diagnosis but blinded to histopathological treatment response, and progression free and overall survival. All 18 F-FDG-PET studies were analyzed quantitatively as previously described (17) . SUVpeak was defined by the average pixel value within a 15 mm 2D ROI drawn around the highest radioactivity concentration in a single plane, which was determined in a 3D volume covering the total tumor area. This approach was used for baseline and follow up scans. SUVs are given as g/ml (SUV = activity concentration in the between independent subgroups. Receiver operating characteristic curves (ROC curves) were used to determine optimal cut-off values for defining metabolic response for the prediction of survival. Fisher's exact test was used to assess association of two categorical variables. A multivariable logistic regression analysis was employed to test for association of early changes in SUVpeak and histopathologic response (≥95% vs. <95%) while controlling for radiotherapy.
Survival probabilities were calculated according to the Kaplan-Meier method and the log-rank test was used for statistical comparison of survival curves between independent subgroups. Multivariable survival analysis was performed by Cox proportional hazard regression and corresponding hazard ratio estimates were provided with ninety-five percent confidence intervals.
Statistical analyses were performed using IBM© SPSS© Statistics software for Windows© (version 19.0, SPSS Inc., Chicago, USA). All statistical tests were performed two-sided and a p-value < 0.05 was considered to indicate statistical significance. No correction of p-values was applied to adjust for multiple tests (19) .
Research. 
Results:
Survival. Seventeen deaths occurred during a median follow-up period of 55 months (maximum follow-up: 76 months). The one-, two-and five-year survival rates were 95±3.0% (n=54), 86±4.6% (n=49) and 68±6.6% (n=14), respectively.
Median time to death was 30.9 months (mean: 27.7; range: 6.9 -50.1).
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18
F-FDG-uptake. SUVpeak averaged 9.5±6.5 g/ml (median, 7.5; range, 2.5-30.7) and was similar in surviving and non-surviving patients 
The sarcoma subtype of histopathological responders included sarcoma nototherwise specified (NOS; n=6), synovial sarcoma (n=2), liposarcoma (one each pleomorphic and dedifferentiated; n=2), rhabdomyosarcoma (pleomorphic; n=1), MPNST (n=1), leiomyosarcoma (non-uterine, n=1), angiosarcoma (n=1) and extra-osseous Ewing's sarcoma (n=1).
Survival analysis.
We have previously identified early and late SUVpeak reductions by 35% and 60% as the best predictors of histopathologic response.
However, histopathologic response was not predictive of patient survival in the current study (p-value: log-rank test=0.401) (Figure 2 ). Therefore, we conducted ROC-analyses to assess the predictive value of early and late changes in curve analysis) were significant predictors of survival (log-rank test: p=0.030 and p=0.034, respectively) ( Figure 2 ). In contrast, late RECIST was not predictive of survival (p=0.801 by log rank test) (Figure 2 ). According to early RECIST, none of the patients responded to therapy. Therefore, the log-rank test was not applicable.
Further univariate survival analyses included other parameters reportedly predictive for sarcoma outcome (18) The value of neoadjuvant therapy in patients with soft tissue sarcoma is controversial (3). In fact, there is no evidence that significant survival benefits are associated with this strategy. Therefore, if reliable early response markers (intermediate endpoint biomarkers) were to become available, non-responding patients could undergo immediate surgery while responding patients would continue the neo-adjuvant treatment. CT measurements cannot provide response assessments in soft tissue sarcoma (2) . Thus, early response assessments with FDG-PET could potentially shorten the duration of ineffective chemotherapy and thereby potentially reduce costs, the number of hospitalizations due to side effects and the use of palliative interventions required to treat these side effects.
As previously shown in a cohort of more than 400 patients, histopathological response to neoadjuvant chemo-or chemo/radiation therapy predicted patient survival (5, 6) . This is in contrast to the findings of the current study and might be explained by the relatively small current sample size. We therefore modeled whether and under which conditions a larger sample size might have resulted in significant response predictions by histopathology. Here we assumed an accrual time of five years, a minimum follow-up of three years, and a five year-overall survival of 63% for histopathological non-responders and 80% for histopathological responders. We further assumed a 25% rate of histopathologic response (approximately the same response rate observed in the current study).
Using these parameters a study population of 250 patients would have been required to achieve statistical significance at a power of 0.80. 
RECIST responders and non-responders had comparable five year survival rates of 62% and 69%, respectively (p=0.80). Using the same parameters as for histopathological response, a study population of 2880 patients would have been required to achieve statistical significance at a power of 0.80. The failure of tumor size based response measurements to separate reliably between responding and non-responding STS may be caused among others by intratumoral hemorrhage, necrosis, and edema all of which may present as mass. It should be noted that in addition to the increasing acceptance of PET imaging as a valuable tool other imaging approaches are under investigation for response assessment in sarcoma and other cancers. These include diffusion weighted magnet resonance imaging (DW-MRI) (23) , and dynamic contrast enhanced (DCE-) MRI (24) , as well as new response criteria / analysis methods, e.g. the previously published Choi criteria. Future prospective multi-center trials need to address whether these cross sectional imaging derived criteria are superior to molecular imaging based response classification systems or provide additional prognostic information.
We and other groups have previously reported that histopathological treatment response can be predicted in sarcoma patients by changes of esophagus (20%) (29), as well as those reported in our previous studies in sarcoma (2) . Moreover, late predictive changes are also comparable to those reported for other cancers including colorectal (62.5%) (30) , squamous cell carcinoma of esophagus (52%) (31) In conclusion, the current study suggests that Figure and Table Legends   Table 1 . Clinical, pathological and treatment characteristics of all 57 patients. 
